IQVIA HOLDINGS INC.
Close on Oct 19, 2026
- Market cap
- $45.15B
- P/E (TTM)
- 32.9
- Dividend yield
- –
About Iqvia
Services-Commercial Physical & Biological Research, SIC 8731
IQVIA provides clinical research services, healthcare intelligence, and commercial solutions to the life sciences and healthcare sectors. The company operates primarily through three reportable segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Its portfolio includes cloud-based software platforms, real-world evidence analytics, strategic consulting, end-to-end clinical trial management, laboratory services, and stakeholder engagement programs. IQVIA serves biotechnology, pharmaceutical, medical device, and consumer health companies, as well as healthcare providers, payers, government bodies, researchers, and pharmacies.
The company operates globally with approximately 93,000 employees across more than 100 countries. It serves over 10,000 clients worldwide, maintaining clinical research networks across nearly 50 locations and conducting healthcare professional and product tracking in dozens of international markets. The provided text does not state the company's headquarters location.
Summary of the business section of Iqvia's latest annual report, written by StockData.
Company profile
Company
- Legal name
- IQVIA HOLDINGS INC.
- Founded
- 2016
- Headquarters
- Durham, NC
- Address
- 2400 Ellis Road 27703
- Phone
- (919) 998-2000
- Website
- iqvia.com
- Employees
- 93,000, Dec 31, 2025
- Industry
- Services-Commercial Physical & Biological Research
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Raleigh, North Carolina
Stock & identifiers
- Ticker
- IQV
- Exchange
- NYSE
- IPO date
- May 9, 2013
- Shares outstanding
- 165M, Jul 21, 2026
- Public float
- $26.50B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1478242
- CUSIP
- 46266C105
- ISIN
- US46266C1053
- LEI
- 549300W3R20NM4KQPH86
- EIN
- 27-1341991
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ari Bousbib | See Remarks, Director | 1,526,400 |
| James G. Berkshire | See Remarks | 13,558 |
| W. Richard Staub | See Remarks | 13,312 |
| Bhavik Patel | See Remarks | 1,348 |
| Keriann Cherofsky | See Remarks | 2,989 |
| Eric Sherbet | See Remarks | 20,999 |
| Michael J. Fedock | See Remarks | 9,472 |
| Bernd Haas | See Remarks | 24,394 |
| Alistair Grenfell | See Remarks | 29,669 |
| Ronald E. Bruehlman | See Remarks | 55,996 |
| Jim Fasano | Director | 1,063 |
| John G. Danhakl | Director | 34,857 |
| Morris Leslie Wims | Director | 2,058 |
| Colleen A. Goggins | Director | 14,453 |
| John M. Leonard | Director | 16,946 |
| William G. Kaelin Jr | Director | – |
| Carol Burt | Director | 7,533 |
| Sheila A. Stamps | Director | 2,058 |
| John Connaughton | Director | 1,047 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Ari Bousbib | $28.13M | $36.07M | $8.87M | $126 | $187 |
| FY2024 Ari Bousbib | $26.73M | $11.45M | $6.58M | $110 | $159 |
| FY2023 Ari Bousbib | $29.15M | $42.29M | $4.52M | $129 | $148 |
| FY2022 Ari Bousbib | $30.14M | $5.96M | $5.01M | $114 | $138 |
| FY2021 Ari Bousbib | $28.62M | $88.42M | $4.40M | $157 | $136 |
| FY2020 Ari Bousbib | $25.58M | $44.63M | $2.89M | $116 | $115 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 5, 2024 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Nov 3, 2017 | Name change | Name changed from Quintiles IMS Holdings, Inc. to IQVIA HOLDINGS INC. |
| Oct 3, 2016 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 22, 2016 | Name change | Name changed from Quintiles Transnational Holdings Inc. to Quintiles IMS Holdings, Inc. |
| Jun 3, 2016 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| May 9, 2013 | IPO | Initial public offering priced (424B4 prospectus) |
| May 2, 2013 | Listing | Registration of securities on an exchange (Form 8-A) |